Adult Growth Hormone Deficiency: from Transition to Senescence

Jens Ol Jørgensen; Kasper Hermansen; Kirstine Stochholm; Anders Juul

doi:10.17458/per.vol16.2018.jhs.adultghdeficiency

Adult Growth Hormone Deficiency: from Transition to Senescence

Jens Ol Jørgensen, Kasper Hermansen, Kirstine Stochholm, Anders Juul

Department of Clinical Medicine

1 Citation (Scopus)

Abstract

The acute metabolic actions of hGH were discovered in GH-deficient adults (GHDA) 60 years ago and placebo controlled trials of prolonged rhGH replacement therapy appeared 30 years after. Untreated GHDA causes excess morbidity and mortality from cardiovascular disease and the clinical features include fatigue, reduced aerobic exercise capacity, abdominal obesity, reduced lean body mass, osteopenia, and elevated levels of circulating cardiovascular risk biomarkers. Several of these abnormalities normalize with GH replacement. Frequent side effects are fluid retention and insulin resistance, which are reversible and dose-dependent. The dose requirement declines with age and is higher in women. Continuation of GH replacement into adulthood is indicated in some patients with childhood-onset disease so the diagnosis must be reassessed. Observational data show that mortality in GH replaced patients is reduced compared to untreated patients. Thus, GH replacement in GHDA has proven beneficial and safe.

Original language	English
Journal	Pediatric Endocrinology Reviews
Volume	16
Issue number	Suppl 1
Pages (from-to)	70-79
ISSN	1565-4753
DOIs	https://doi.org/10.17458/per.vol16.2018.jhs.adultghdeficiency
Publication status	Published - 1 Sept 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.17458/per.vol16.2018.jhs.adultghdeficiency

Cite this

@article{a7c1b07eaaa840d48edc598a680fc231,

title = "Adult Growth Hormone Deficiency: from Transition to Senescence",

abstract = "The acute metabolic actions of hGH were discovered in GH-deficient adults (GHDA) 60 years ago and placebo controlled trials of prolonged rhGH replacement therapy appeared 30 years after. Untreated GHDA causes excess morbidity and mortality from cardiovascular disease and the clinical features include fatigue, reduced aerobic exercise capacity, abdominal obesity, reduced lean body mass, osteopenia, and elevated levels of circulating cardiovascular risk biomarkers. Several of these abnormalities normalize with GH replacement. Frequent side effects are fluid retention and insulin resistance, which are reversible and dose-dependent. The dose requirement declines with age and is higher in women. Continuation of GH replacement into adulthood is indicated in some patients with childhood-onset disease so the diagnosis must be reassessed. Observational data show that mortality in GH replaced patients is reduced compared to untreated patients. Thus, GH replacement in GHDA has proven beneficial and safe.",

author = "J{\o}rgensen, {Jens Ol} and Kasper Hermansen and Kirstine Stochholm and Anders Juul",

note = "Copyright{\textcopyright} of YS Medical Media ltd.",

year = "2018",

month = sep,

day = "1",

doi = "10.17458/per.vol16.2018.jhs.adultghdeficiency",

language = "English",

volume = "16",

pages = "70--79",

journal = "Pediatric Endocrinology Reviews",

issn = "1565-4753",

publisher = "YS Medical Media Ltd.",

number = "Suppl 1",

}

TY - JOUR

T1 - Adult Growth Hormone Deficiency

T2 - from Transition to Senescence

AU - Jørgensen, Jens Ol

AU - Hermansen, Kasper

AU - Stochholm, Kirstine

AU - Juul, Anders

PY - 2018/9/1

Y1 - 2018/9/1

N2 - The acute metabolic actions of hGH were discovered in GH-deficient adults (GHDA) 60 years ago and placebo controlled trials of prolonged rhGH replacement therapy appeared 30 years after. Untreated GHDA causes excess morbidity and mortality from cardiovascular disease and the clinical features include fatigue, reduced aerobic exercise capacity, abdominal obesity, reduced lean body mass, osteopenia, and elevated levels of circulating cardiovascular risk biomarkers. Several of these abnormalities normalize with GH replacement. Frequent side effects are fluid retention and insulin resistance, which are reversible and dose-dependent. The dose requirement declines with age and is higher in women. Continuation of GH replacement into adulthood is indicated in some patients with childhood-onset disease so the diagnosis must be reassessed. Observational data show that mortality in GH replaced patients is reduced compared to untreated patients. Thus, GH replacement in GHDA has proven beneficial and safe.

AB - The acute metabolic actions of hGH were discovered in GH-deficient adults (GHDA) 60 years ago and placebo controlled trials of prolonged rhGH replacement therapy appeared 30 years after. Untreated GHDA causes excess morbidity and mortality from cardiovascular disease and the clinical features include fatigue, reduced aerobic exercise capacity, abdominal obesity, reduced lean body mass, osteopenia, and elevated levels of circulating cardiovascular risk biomarkers. Several of these abnormalities normalize with GH replacement. Frequent side effects are fluid retention and insulin resistance, which are reversible and dose-dependent. The dose requirement declines with age and is higher in women. Continuation of GH replacement into adulthood is indicated in some patients with childhood-onset disease so the diagnosis must be reassessed. Observational data show that mortality in GH replaced patients is reduced compared to untreated patients. Thus, GH replacement in GHDA has proven beneficial and safe.

U2 - 10.17458/per.vol16.2018.jhs.adultghdeficiency

DO - 10.17458/per.vol16.2018.jhs.adultghdeficiency

M3 - Journal article

C2 - 30378784

SN - 1565-4753

VL - 16

SP - 70

EP - 79

JO - Pediatric Endocrinology Reviews

JF - Pediatric Endocrinology Reviews

IS - Suppl 1

ER -

Adult Growth Hormone Deficiency: from Transition to Senescence

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this